Notably, oncogenic activation of this pathway in breast cancer is mainly attributed to the mutation of genes encoding PI3K subunits, including p110α (PIK3CA) and p110β (PIK3CB), where PIK3CA mutations were reported in 30–40% of breast cancer patients [9,10]. This evidence concerns the gene PIK3CA and breast cancer.